Smith & Nephew Unveils Long-Term Growth Targets Amid Q4 Earnings Momentum

The release of Smith & Nephew’s fourth-quarter results and the introduction of its FY26 and FY28 outlook marks a pivotal moment for the London-based medical technology firm. For several years, Smith & Nephew has been navigating a complex turnaround strategy, dubbed the 12-Point Plan, aimed at addressing supply chain vulnerabilities and improving the profitability of its Orthopaedics division. The introduction of long-term guidance through 2028 suggests that the company is now moving beyond these foundational fixes and into a phase of aggressive market share capture and margin expansion.

The Orthopaedics segment remains the core engine of the company’s portfolio. In recent quarters, Smith & Nephew has focused on regaining ground in the hip and knee replacement markets, where it has historically lagged behind competitors like Stryker and Zimmer Biomet. Central to this effort is the CORI Surgical System, a handheld robotic platform that offers a smaller footprint and lower cost of entry than the large-arm robotic systems favored by competitors. By integrating CORI across its joint replacement and sports medicine portfolios, Smith & Nephew is positioning itself to capitalize on the shift of elective procedures toward Ambulatory Surgery Centers (ASCs), where space and efficiency are at a premium.

“

Smith & Nephew has historically struggled to maintain margins in the 20% range, often falling into the mid-to-high teens due to inflationary pressures and logistical inefficiencies.

Sports Medicine and ENT (Ear, Nose, and Throat) continue to be high-growth areas for the company. The recent partnership with SI-BONE, which involves the distribution of specialized sacropelvic solutions, illustrates Smith & Nephew’s strategy of using its massive global sales force to pull through innovative third-party products. This capital-light approach to portfolio expansion allows the company to drive revenue growth without the immediate R&D overhead associated with internal development. Analysts will be watching closely to see if the FY26 and FY28 targets include further M&A activity or if the company intends to rely primarily on organic growth and strategic partnerships.

Advanced Wound Management, the third pillar of the business, provides a steady, recurring revenue stream that balances the more cyclical nature of surgical hardware. While this segment has faced pricing pressures in certain European markets, the demand for specialized dressings and negative pressure wound therapy (NPWT) remains robust globally, driven by an aging population and the rising prevalence of chronic conditions like diabetes. The FY28 outlook likely assumes a stabilization of these markets and a continued push into higher-margin biologics and bioactive wound care products.